TO THE EDITOR
Although most patients with acute myeloid leukemia (AML) will obtain a complete remission (CR), the majority will eventually relapse and die from their disease. Early detection of minimal residual disease (MRD) would offer the possibility of implementing salvage therapies prior to overt clinical relapse. 1 So far, PCR assays for MRD in AML patients have mainly amplified unique genetic sequences created by any one of the three common translocations: t(8;21), t(15;17), and inv(16). 2 However, only about 25% of AML patients will have one of these translocations, 1, 2 and moreover in such cases it is necessary to carefully evaluate the different expression of fusion transcripts. More recently, the overexpression of WT1 gene has been considered as a possible MRD marker in AML. 1 The FLT3 gene encodes a tyrosine kinase receptor that regulates proliferation and differentiation of hematopoietic stem cells. 3 The internal tandem duplication of the FLT3 gene (FLT3/ ITD) is the most common mutation in both adult and childhood AML occurring in 10-27% of patients. 3 It has recently been found that 90% of FLT3/ITDs occur in AML patients with no previously defined molecular marker. 3 Therefore, FLT3/ITD may provide an adequate MRD marker for nearly 25% of AML patients, who have no alternative markers.
We developed a real time quantitative-PCR (RQ-PCR) specific assay for FLT3/ITD. We used this method to test FLT3/ITD as a MRD marker for 19 pediatric AML cases, demonstrating high sensitivity and specificity in 17 patients. We further monitored the follow-up of eight childhood AML patients, demonstrating that the different FLT3/ITD levels detected by RQ-PCR in the follow-up of all patients predicted the clinical trend.
We analyzed a series of 19 pediatric patients, 11 male and eight female, with de novo AML positive for FLT3/ITD, followed at our Institute between January 1985 and October 2003. The average age at diagnosis was 9.3, ranging between 1.6 and 17 years. The mean WBC count at diagnosis was 99 Â 10 9 /l (range 7 Â 10 9 -296 Â 10 9 /l), with a percentage of blasts ranging between 57 and 96%. According to conventional clinical, morphological (FAB), and cytochemical criteria, patients were diagnosed as M1 (
, and M0 (n ¼ 1). Either fresh or thawed mononuclear cells (MNC) were obtained after centrifugation on a density gradient using Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden), washed three times in phosphate-buffered saline (PBS) and re-suspended at 0.5-1.0 Â 10 6 /ml in PBS containing 0.5% bovine serum albumin (PBS-BSA). DNA was extracted by using phenol-chloroform procedure from bone marrow (BM)-MNC collected at diagnosis, and in eight cases at different points of follow-up.
The ITD presence in all patients at diagnosis was detected by PCR on genomic DNA, using 11F and 12R primers. 4 Aberrant PCR products were excised from agarose gel and cloned into the pMOSBlue vector (pMOSBlue Blunt Ended Cloning Kit, Amersham Pharmacia Biotec, Buckinghamshire, UK). Plasmidic DNA from recombinant colonies was sequenced on an ABI PRISM 377 Automated Sequencer (Applied Biosystems, Foster City, CA, USA).
A general schema of the RQ-PCR approach is shown in Figure 1a . The patient-specific forward primer, the probe, and the reverse primer were designed using Primer Express software (Applied Biosystems, Foster City, CA, USA). The patient-specific forward primer was designed to preferentially anneal to the joining region between the wild-type sequence and the beginning of the FLT3/ITD. We designed three different common reverse primers and two fluorescent probes, in order to cover any duplication; in particular, the common reverse primer 5 0 -GTACGTGCATTTTAAAGATTTTCCAA-3 0 , and the probe 5
0 -FAM-AGAATGGAATGTGCCAAATGTTTCTGCAG-3 0 -Tamra on intron 11 were used for duplication occurring in exon 11; in only one case (patient 19) a different reverse primer 5 0 -GGTGAGTACGTGCATTTTAAAGATTTT-3 0 was used, according to the software choice. The reverse primer 5 0 -CAACCTG-GATTGAGACTCCTGTTT-3 0 and the fluorescent probe 5 0 -FAM-TGATGAACGCAACAGCTTATGGAATTAGCA-3 0 -Tamra, both on exon 12, were used for ITD occurring downstream (patient 17). For RQ-PCR analysis, the TaqMan PCR core reagent kit was used (Applied Biosystems, Foster City, CA, USA).
Reaction mixtures of 25 ml contained 2.5 ml TaqMan buffer A (Applied Biosystems) with the ROX dye as the passive reference, 5 mM MgCl 2 , 0.3 mM dATP, 0.3 mM dCTP, 0.3 mM dGTP, and 0.6 mM dUTP, 5 mM primers, 1.25 U AmpliTaq Gold, 1 U uracil-N-glucosidase (UNG), and 500 ng of DNA. The amplification protocol consisted of 10 min at 951C (inactivation of UNG, denaturation of target DNA, and activation of AmpliTaq Gold), followed by target amplification via 50 cycles of 15 s at 951C and 1 min at 58-62.51C (Table 1) .
Real-time analysis was performed on the ABI PRISM 7700 or 7900 Sequence Detection System containing a 96-well thermal cycler (Applied Biosystems, Foster City, CA, USA). The RQ-PCR was optimized for each patient by changing the annealing temperature in order to increase sensitivity. All samples were tested in triplicate.
To test sensitivity and specificity of the assay, 10-fold serial dilutions were prepared starting from 500 ng of diagnostic BM-MNC DNA mixed with DNA extracted from PB-MNC of a pool of five different healthy donors. To correct for the quantity and quality of DNA in follow-up samples, the albumin gene DNA was amplified (TaqMan s Control Genomic DNA, Applied Biosystems). Standard curves for FLT3/ITD and albumin were established by amplifying a 10-fold serial dilution of target DNA in DNA from healthy donors PB-MNC or water, respectively. Subsequently, the albumin-normalized diagnostic value was set as 1.0 and FLT3/ITD normalized specific quantities in follow-up samples were related to that at diagnosis.
The RQ-PCR approach was applied to 19 AML cases positive for FLT3/ITD at diagnosis (Table 1) . A patient-specific primer was developed for all the patients but one (patient 9); in this latter case the design of a specific primer was not possible because the junction between FLT3/wt and FLT3/ITD corresponded to the wild-type FLT3 sequence. In patient 2, two forward specific primers were designed and tested, but in both cases high background levels were observed, making their sensitivity below 10 À2 . In 16 out of 17 cases a single forward patient-specific RQ-PCR primer was designed. In only one case (patient 1) we designed and tested three different forward primers, according to the Primer Express software (Applied Biosystems, Foster City, CA, USA); only one of them allowed to achieve a 10 À4 sensitivity. Figure 1 shows the methodological approach (a), and an example of dilution curves (b).
As shown in Table 1 , the maximal reproducible sensitivity was 10 À4 for 15 patients, 10 À5 for one patient and 10 À3 for one patient. The maximal reproducible sensitivity was defined as the dilution in which all replicates were positive within a 1.5 Ct range, and the highest cycle threshold (Ct) of the replicates was at least 1.0 Ct lower than the lowest replicate of the background amplification. 5 Amplifications, even in one out of three wells, below the maximal reproducible sensitivity but still 1.0 Ct lower than the lowest replicate of the background have been considered as 'positive not quantifiable'. This was the case in 13 out of the 17 patients analyzed. High correlation coefficients (40.95) were obtained, allowing an accurate assessment of the quantity of FLT3/ITD in unknown samples. All amplification plots were analyzed by positioning the threshold at 1.0, in order to compare different experiments. In all cases this value was in the linear range of all dilutions. The mean Ct for undiluted DNA samples was 26.4 (range 24.6-29). The mean slope of the dilution curves was 3.6. In only one case the slope was higher than 4.0 (patient 10), indicating a quite inefficient PCR, making the quantification uncertain.
In eight patients (cases 3, 4, 7, 11, 12, 17, 18, and 19) we analyzed the FLT3/ITD levels at different time points during therapy (Figure 2) , in order to proof the feasibility of MRD monitoring by FLT3/ITD. The patients were treated with different therapeutic protocols. In patients 3, RQ-PCR monitoring showed a progressive decrease of the FLT3/ITD positive clone in the first 3 months of therapy. He received allogeneic BMT 5 months after diagnosis, he showed low positive MRD levels at 7 months and resulted negative at two subsequent time points, 13 and 21 months after diagnosis, with a sensitivity of 10 À5 . Patients 4 was resistant to therapy, as shown by the morphological analysis of the BM 1 month after diagnosis (blasts 62%). By means of qualitative PCR, we analyzed the FLT3/ITD during the progression of the disease and we observed a progressive increase of the FLT3/ITD allele and a progressive decrease of the wild-type allele, until disappearance at 3 months (data not shown). In order to precisely quantify the level of the ITD, we applied the specific RQ-PCR method, and we found that the FLT3/ITD allele quantity was increased four-fold after 1 month and eight-fold after 2 and 3 months, with respect to presentation. At diagnosis the patient presented 84% of blast cells; to explain the further increase of FLT3/ITD we hypothesized that a minor subclone with FLT3/ITD and FLT3 wt deletion at diagnosis underwent a selective growth. In patient 7, although an early decrease of the FLT3/ITD levels was observed, after 2 months of therapy the patient presented a dramatic increase of the FLT3/ITD levels, which anticipated the increase of the blasts count, as documented by the morphological analysis of the BM (blasts o5% after 2 months, 70% after 3 months). At 2.5 months he suffered from BM relapse (April 2000) and was treated with a modified consolidation schedule of the AML BFM 93 protocol, including VP16, High Doses Ara-C and L-Asparaginase. Between months 3 and 5, despite a morphological remission of the disease, the FLT3/ITD levels persisted high; the patient had a morphological rebound at 5th month of therapy. The FLT3/ITD resulted negative at the time points after BMT. Patient 11 achieved hematological remission but showed persistently high levels of FLT3/ITD and died from progression of disease after 5 months. Unfortunately, only one time point was available in the first 3 months of therapy for patient 12. He showed very high FLT3/ITD levels at 1 month, then low levels (2 Â 10
À4
) after 3 months of the therapy. The patient then relapsed at 5 months, showing again high levels of the same FLT3/ITD, even higher than the ones at diagnosis. The previous analysis was performed 45 days before clinical relapse and showed higher levels of FLT3/ITD. Patient 17 and patient 19 showed a progressive decrease of FLT3/ITD in the first months, and, at the time of last observation, both the patients were in CCR. RQ-PCR monitoring in patient 18 demonstrated the initial progressive decrease to negative levels. After he received auto-BMT, 6 months after diagnosis, the FLT3/ITD levels progressively increased. The patient relapsed at 10 months, with a molecular relapse detectable 1 month before the clinical relapse.
In conclusion, the results of FLT3/ITD monitoring in eight AML patients were in agreement with the clinical course of the disease, further indicating that FLT3/ITD could potentially be utilized as a marker of MRD in AML. In particular, FLT3/ITD may potentially provide an adequate MRD marker for nearly 20-25% of AML patients with no alternative markers. The MRD monitoring at DNA level can potentially have several advantages: (i) DNA is less sensitive to degradation; (ii) in contrast to fusion gene transcripts (and comparable to Ig/TCR gene rearrangements in ALL), only one PCR target is present per cell, which makes quantitation easier. Moreover, with respect to the RT-PCR for fusion genes, the FLT3/ITDs at the DNA level differ in each patient so that patient-specific RQ-PCR strategies can be applied.
So far, specific RQ-PCR of FLT3/ITD was reported in only four patients harboring FLT3/ITDs of different lengths and locations, Two additional specific primers were designed and tested, but as they did not show high sensitivity they were not further used for monitoring. c Two specific primers were designed and tested, but no amplification was obtained. The design of a specific primer was not possible, because by chance the specific sequence resulting after the FLT3 duplication was fully homologue to the wild-type FLT3 sequence.
Correspondence using a 'nested' approach. 6 Schnittger et al mentioned the use of patient-specific primer/probe sets for RQ-PCR, using Light Cycler technology (Blood 2001;98:581a). However, we are not aware of any report with a detailed description of the method. In the present study, using a patient-specific PCR primer approach, we successfully performed a single-step RQ-PCR in 17 out of 19 pediatric AML patients. The maximal reproducible sensitivity was 10 À4 for 15 patients, 10 À5 for one patient, and 10 À3 for one patient. The use of FLT3/ITD as a MRD marker has been recently questioned, 7 by the fact that FLT3/ITD can be present at relapse of cases negative at diagnosis and vice versa. This would indicate that FLT3/ITD is a secondary mutation, not sufficient to cause AML. As a consequence, the loss of the PCR target might lead to false-negative MRD results. However, the results are still controversial. Shih et al 8 showed that one of 17 ITD patients at presentation were FLT3/wt at relapse; in this case, relapse occurred after unknown time from the diagnosis and, consequently, the presumed AML relapse in this single patient might in fact represent a secondary leukemia. Schnittger et al (Blood 2001;98:581 abstract) reported that all 25 patients with a mutation at presentation relapsed with the same marker. Studies by Kottaridis et al 9 demonstrated that five (25%) of 20 patients ITD þ at presentation lost their mutation at relapse. However, in the published studies, the sensitivity of qualitative FLT3/ITD detection assays was only around 0.5%, corresponding to one mutated cell out of 200 normal cells. 8, 9 In summary, only prospective studies on large series of AML patients will definitively test the stability of FLT3/ITD and its predictive value for MRD monitoring during follow-up. Indeed, the FLT3/ITD stability is not far different from what observed in ALL patients monitored by immunoglobulin and T-cell receptor rearrangements, where the stability of the clonal marker is around 70%. 10 Moreover, the emergence of FLT3 mutations has been recently identified as a new mechanism of secondary resistance in FLT3-ITD transformed hematopoietic cells after prolonged exposure to the PTK inhibitor SU5614 in vitro. 3 These data demonstrated that distinct FLT3 gene mutations are acquired or selected in transformed cell lines treated with FLT3 inhibitors. These findings will have a profound impact on the design of clinical studies evaluating FLT3 inhibitors in patients with AML. 3 As a further application, the herewith introduced RQ-PCR method will allow to backtrack the different FLT3/ITD subclones during the patient follow-up, which could be of potential interest to understand the natural history of the alteration. The patient-specific RQ-PCR assay using primer sets that cover the junction regions of the ITD permits the mutation but not wildtype alleles to be amplified, and allows to quantify specifically the FLT3 mutated allele. An analogue RQ-PCR method to monitor the FLT3 wt alleles in both leukemic and normal cells can be potentially developed, in order to evaluate whether the FLT3 ITD/wt ratio can have an added prognostic value in AML patients. For patients with more than one FLT3/ITD, all mutations can be monitored during follow-up, using specific primers.
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